Browse Prior Art Database

Evotaz tablet

IP.com Disclosure Number: IPCOM000244190D
Publication Date: 2015-Nov-22
Document File: 2 page(s) / 274K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a PDF file.
This is the abbreviated version, containing approximately 87% of the total text.

Page 01 of 2

Evotaz tablet

1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4- yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate has the following chemical structure:

Chromatographic purity of Evotaz tablet (Lot No. -PVWYB, Expiry date: June 2016, Bristol-Mayers

Squibb, US market):

One Evotaz tabletwas weighed, grinded to a powder and dissolved by sonication for 10 min in 75 ml of diluent (75% 0.15% TFA in Water: 25%Acetonitrile). The resulting solution was filtered and injected into the HPLC system.

The obtained purity results are as follows:

Purity of: 1,3-thiazol-5-ylmethyl [(2R,5R)-5-

{[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-

thiazol-4-yl]methyl}carbamoyl)amino]-4-

Impurity Profile , RRT , % on area

(morpholin-4-yl)butanoyl]amino}-1,6-

diphenylhexan-2-yl]carbamate, %


1.00


0.75 0.98 1.07 1.21


99.0


0.04 0.72 0.06 0.05

The content of the most prominent diasteriomer 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2R)-2- [(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4- yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate, as depicted in the picture below, in the Evotaz tablet (Lot No. -PVWYB, Expiry date: June 2016, Bristol-Mayers Squibb, US market): was determined

to be less than 0.73 %;

O

N

Ph

N

S

N O

NH O

HN

Ph

NH O

O N S

1


Page 02 of 2

The content of enantiomer 1,3-thiazol-5-ylmethyl [(2S,5S)-5-{[(2R)-2-[(methyl{[2-(propan-2-yl)-1,3- thiazol-4-yl]methyl}carbamoyl)amino]-4-(mor...